U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17ClN2O5
Molecular Weight 388.802
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VER-50589

SMILES

CCNC(=O)C1=NOC(=C1C2=CC=C(OC)C=C2)C3=CC(Cl)=C(O)C=C3O

InChI

InChIKey=JXPCDMPJCKNLBY-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O5/c1-3-21-19(25)17-16(10-4-6-11(26-2)7-5-10)18(27-22-17)12-8-13(20)15(24)9-14(12)23/h4-9,23-24H,3H2,1-2H3,(H,21,25)

HIDE SMILES / InChI

Molecular Formula C19H17ClN2O5
Molecular Weight 388.802
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/19244114 | https://www.ncbi.nlm.nih.gov/pubmed/24292262

VER-50589 is an isoxazole compound that inhibits a heat shock protein Hsp90. Mean cellular antiproliferative GI(50) value for VER-50589 for a human cancer cell line panel were 78 nM/L, showing a 9-fold potency gain for the isoxazole. VER-50589 shows favorable pharmacokinetics and impairs tumor growth (colon cancer) in animal model. Glioblastoma cells do not acquire resistance to VER-50589 and resistance to other Hsp90 inhibitors does not produce cross-resistance to VER-50589.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
21.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
2007 Apr
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
2008 Jan 24
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
2017 Mar
Patents

Sample Use Guides

Nine daily doses of 100 mg/kg
Route of Administration: Intraperitoneal
VER-50589 inhibited HUVEC proliferation with GI50 values of 19 nM/L, respectively. The nontumorigenic human breast (MCF10a) and prostate (PNT2) epithelial cells exhibited higher GI50 values for VER- 50589 when compared with their respective mean GI50 (330 nM/l and 179.5 nM/l respectively) values against cancer cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:43:53 GMT 2023
Edited
by admin
on Sat Dec 16 15:43:53 GMT 2023
Record UNII
H4E4ND635H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VER-50589
Code English
3-Isoxazolecarboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-
Systematic Name English
5-(5-Chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-3-isoxazolecarboxamide
Systematic Name English
5-(5-Chloranyl-2,4-bis(oxidanyl)phenyl)-N-ethyl-4-(4-methoxyphenyl)-1,2-oxazole-3-carboxamide
Systematic Name English
Code System Code Type Description
PUBCHEM
135446210
Created by admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
PRIMARY
CAS
747413-08-7
Created by admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
PRIMARY
FDA UNII
H4E4ND635H
Created by admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
PRIMARY